Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Poolbeg Pharma PLC
POLBCurrent price
9.1 GBX
+0.1 GBX (+1.11%)
Last closed
9 GBX
Company
www.poolbegpharma.com
ISIN
GB00BKPG7Z60
Sector
Healthcare
Industry
Biotechnology
Exchange
London Exchange
Capitalization
41 535 694 GBX
Yield for 12 month
+34.81 %
1Y
3Y
5Y
10Y
15Y
POLB
Poolbeg Pharma PLC operates as a biopharmaceutical company, engages in the development and commercialization of medicines for unmet medical needs in the United Kingdom. It develops POLB 001, which is in phase 1 clinical study for cancer immunotherapy-induced cytokine release syndrome and severe influenza. The company is also developing oral encapsulated GLP-1R agonist for obesity and diabetes treatment; influenza and respiratory syncytial virus AI programme; POLB 002, an inlicensed firstinclass broad spectrum RNAbased immunotherapy for respiratory virus infections; and POLB 003, an intramuscular vaccine to prevent Melioidosis. In addition, it has a license to encapsulation technology for oral vaccine delivery platform that delivers immune stimulating antigens to various areas of the gut. Further, the company is involved in the development of biomarker platform to identify those at risk of developing severe disease; and vaccine discovery platform, a model-derived discovery platform to identify new vaccine candidates. Poolbeg Pharma plc was incorporated in 2021 and is headquartered in London, the United Kingdom. Address: 40 Bank Street, London, United Kingdom, E14 5NR
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
1 622.41 GBXP/E ratio
–Dividend Yield
–Current Year
–
Last Year
–
Current Quarter
–
Last Quarter
–
Current Year
-2 602 268 GBX
Last Year
-2 602 268 GBX
Current Quarter
-1 301 095 GBX
Last Quarter
–
Key Figures POLB
1 year
3 years
5 years
10 years
EBITDA
-5 110 358 GBX
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-21.33 %
PEG Ratio
–
Return On Equity TTM
-30.19 %
Wall Street Target Price
1 622.41 GBX
Revenue TTM
–
Book Value
0.025 GBX
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
–
Earnings per share
-0.01 GBX
Diluted Eps TTM
-0.01 GBX
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics POLB
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History POLB
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
–
Payout Ratio
–
Last Split Date
–
Dividend Date
–
Stock Valuation POLB
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
–
Enterprise Value EBITDA
-6.5923
Price Book MRQ
3.3336
Financials POLB
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators POLB
For 52 weeks
6.53 GBX
15.78 GBX
50 Day MA
9.56 GBX
Shares Short Prior Month
–
200 Day MA
11.03 GBX
Short Ratio
–
Shares Short
–
Short Percent
–
BeatStart